DNA methylation in cancer development, diagnosis and therapy - Multiple opportunities for genotoxic agents to act as methylome disruptors or remediators

Mutagenesis

Volumn 26, Issue 4, 2011, Pages 475-487

  Lewandowska, Joanna ^a   Bartoszek, Agnieszka ^a  

^a GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 METHYLCYTOSINE; 5,6 DIHYDROAZACITIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; CARCINOGEN; DNA METHYLTRANSFERASE; DOXORUBICIN; EPIGALLOCATECHIN GALLATE; FAZARABINE; HYDRALAZINE; MERCAPTOPURINE; MG 98; MITOXANTRONE; N PHTHALOYLTRYPTOPHAN; PROCAINAMIDE; PROCAINE; ZEBULARINE;

ANTITUMOR GENE; CANCER CELL; CANCER DIAGNOSIS; DATA ANALYSIS; DNA ADDUCT; DNA METHYLATION; DNA MODIFICATION; DNA REPAIR; DRUG HALF LIFE; ENZYMOLOGY; EPIGENETICS; GENE SILENCING; GENOTOXICITY; HUMAN; MEDICAL RECORD; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; DNA DAMAGE; DNA METHYLATION; GENE SILENCING; HUMANS; MUTAGENS; NEOPLASMS;

EID: 79959744436     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/ger019     Document Type: Review

References (137)

1. Kouzarides, T. (2007) Chromatin modifications and their function. Cell, 128, 693-705.
2. Lippman, Z. and Martienssen, R. (2004) The role of RNA interference in heterochromatic silencing. Nature, 431, 364-370. (Pubitemid 39265677)
3. Law, J. A. and Jacobsen, S. E. (2010) Establishing, maintaining and modyfying DNA methylation patterns in plants and animals. Nat. Rev. Genet., 11, 204-219.
4. Yu, W., Gius, D., Onyango, P., Muldoon-Jacobs, K., Karp, J., Feinberg, A. P. and Cui, H. (2008) Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature, 451, 202-206.
5. Buhler, M. and Moazed, D. (2007) Transcription and RNAi in heterochromatic gene silencing. Nat. Struct. Mol. Biol., 14, 1041-1048.
6. Rosok, O. and Sioud, M. (2004) Systematic identification of sense-antisense transcripts in mammalian cells. Nat. Biotechnol., 22, 104-108.
7. Szyf, M. (2005) DNA methylation and demethylation as targets for anticancer therapy. Biochemistry, 70, 533-549.
8. Kubicek, S., Schotta, G., Lachner, M. et al. (2006) The role of histone modifications in epigenetic transitions during normal and perturbed development. New Approaches to Cancer Therapy Series: Ernst Schering Foundation Symposium Proceedings, Vol. 57, Springer, Germany, pp. 1-27.
9. Baker, M. (2010) Epigenome: mapping in motion. Nat. Methods., 7, 181-185.
10. Peedicayil, J. (2006) Epigenetic therapy - a new developmnet in pharmacology. Indian J. Med. Res., 123, 17-24.
11. Espada, J. and Esteller, M. (2007) Epigenetic control of nuclear architecture. Cell. Mol. Life Sci., 64, 449-457.
12. Ramsahoye, B. H., Biniszkiewicz, D., Lyko, F., Clark, V., Bird, A. and Jaenisch, R. (2000) Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc. Natl Acad. Sci. USA., 97, 5237-5242.
13. Lister, R., Pelizzola, M., Dowen, R. H. et al. (2009) Human DNA methylomes at base resolution show widespread epigenomic differences. Nature, 462, 315-322.
14. Kriaucionis, S. and Heintz, N. (2009) The nuclear base 5-hydroxymethylcytosine is present in Purkinje neurons and brain. Science, 324, 929-930.
15. Tahiliani, M., Koh, K. P., Shen, Y. et al. (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science, 324, 930-935.
16. Riggs, A. D. (1975) X inactivation, differentiation, and DNA methylation. Cytogenet. Cell Genet., 14, 9-25.
17. Holliday, R. and Pugh, J. E. (1975) DNA modification mechanisms and gene activity during development. Science, 187, 226-232.
18. Pradhan, S. and Estève, P.-O. (2003) Mammalian DNA (cytosine-5)methyltransferases and their expression. Clin. Immunol., 109, 6-16.
19. Vertino, P. M., Sekowski, J. A., Coll, J. M., Applegren, N., Han, S., Hickey, R. J. and Malkas, L. H. (2002) DNMT1 is a component of a multiprotein DNA replication complex. Cell Cycle, 1, 416-423.
20. Zhao, Q., Rank, G., Tan, Y. T. et al. (2009) PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat. Struct. Mol. Biol., 16, 304-311.
21. Wilkins, J. F. (2005) Genomic imprinting and methylation: epigenetic canalization and conflict. Trends Genet, 21, 356-365.
22. Robertson, K. D. (2005) DNA methylation and human disease. Nat. Rev. Genet., 6, 597-610.
23. Jones, A. P. (2002) DNA methylation in cancer. Oncogene, 21, 5358-5360.
24. Goll, G., Kirpekar, F., Maggert, K. A., Yoder, J. A., Hsieh, J. A., Zhang, X. and Golic, K. G. (2006) Methylation of tRNA Asp by the DNA methyltransferase homolog Dnmt2. Science, 311, 395-398.
25. Ooi, S. K. T. and Bestor, T. H. (2008) The colorful history of active DNA demethylation. Cell, 133, 1145-1148.
26. Kapoor, A., Agius, F. and Zhu, J.-K. (2005) Preventing transcriptional gene silencing by active DNA demethylation. FEBS Lett., 579, 5889-5898. (Pubitemid 41484134)
27. Kangaspeska, S., Stride, B., Metivier, R., Polycarpou-Schwarz, M., Ibberson, D., Carmouche, R. P., Benes, V., Gannon, F. and Reid, G. (2008) Transient cyclical methylation of promoter DNA. Nature, 452, 112-116.
28. Métivier, R., Gallais, R., Tiffoche, C. et al. (2008) Cyclical DNA methylation of a transcriptionally active promoter. Nature, 452, 45-50. (Pubitemid 351355084)
29. Popp, C., Dean, W., Feng, S., Cokus, S. H., Andrews, S., Pellegrini, M., Jacobsen, S. E. and Reik, W. (2010) Genome-wide erasure of DNA methylation in mouse primordial germ cells is affected by AID deficiency. Nature, 463, 1101-1105.
30. Bhutani, N., Brady, J. J., Damian, M., Sacco, A., Corbel, S. Y. and Blau, H. M. (2010) Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature, 463, 1042-1047.
31. Parry, T. E. (2006) Mutagenic mechanisms in leukemia and cancer: a new concept cytosine lack could be as mutagenic as cytosine deamination. Leuk. Res., 30, 1079-1083.
32. Zingg, J. M., Shen, J. C., Yang, A. S., Rapoport, H. and Jones, P. A. (1996) Methylation inhibitors can increase the rate of cytosine deamination by cytosine-5-DNA methyltransferase. Nucleic Acid Res., 24, 3267-3275.
33. Kasai, H. and Kawai, K. (2009) DNA methylation at the C-5 position of cytosine by methyl radicals: a possible role for epigenetic change during carcinogenesis by environmental agents. Chem. Res. Toxicol., 22, 984-989.
34. Zardo, G., Fazi, F., Travaglini, L. and Nervi, C. (2005) Dynamic and reversibility of heterochromatic gene silencing in human disease. Cell Res., 15, 679-690. (Pubitemid 41673852)
35. Klose, R. J. and Bird, A. P. (2006) Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci., 31, 89-187.
36. Doi, A., Park, I.-H., Wen, B. et al. (2009) Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet., 41, 1350-1353.
37. Nabilsi, N. H., Broaddus, R. R. and Loose, D. S. (2009) DNA methylation inhibits p53-mediated survivin repression. Oncogene, 28, 1-5.
38. Rodenhiser, D. and Mann, M. (2006) Epigenetics and human disease: translating basic biology into clinical applications. CMAJ, 3, 341-348. (Pubitemid 43235307)
39. Erlich, M. (2002) DNA hypomethylation, cancer, the immunodeficiency, centromeric region instability, facial anomalies syndrome and chromosomal rearragements. J. Nutr., 132, 2424S-2429S.
40. Teodoridis, J. M., Strathdee, G. and Brown, R. (2004) Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist. Updat., 7, 267-278.
41. Szyf, M. (2003) Targeting DNA methylation in cancer. Ageing Res. Rev., 2, 299-328.
42. Zhang, Z., Karam, J., Frankel, E., Sagalowsky, A. and Hsieh, J.-T. (2006) The application of epigenetic modifiers on the treatment of prostate and bladder cancer. Urol. Oncol., 24, 152-160.
43. Ushijima, T. (2005) Detection and interpretation of altered methylation patterns in cancer cells. Nat. Rev. Cancer, 5, 223-231.
44. Garcia, J. M., Silvia, J., Pena, C. et al. (2004) Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer, 41, 117-124. (Pubitemid 39096737)
45. Lujambio, A., Calin, G. A., Villanueva, A. et al. (2008) A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl Acad. Sci. USA., 105, 13556-13561.
46. Davies, C. D. (2004) DNA methylation, cancer susceptibility, and nutrient interactions. Exp. Biol. Med., 229, 988-995.
47. Johanning, G. L., Heimburger, D. C. and Piyathilake, C. J. (2002) DNA methylation and diet in cancer. J. Nutr., 132, 3814S-3818S.
48. Huang, S. (2002) Histone methyltransferases, diet nutrients and tumor suppressors. Nat. Rev. Cancer, 2, 469-472.
49. Prinz-Langenohl, R., Fohr, I. and Pietrzik, K. (2001) Beneficial role for folate in the prevention of colorectal and breast cancer. Eur. J. Nutr., 40, 98-105.
50. Kim, Y.-I. (2005) Nutritional epigenetics: impact of folate deficiency on DNA methylation and colon cancer susceptibility. J. Nutr., 135, 2703-2709.
51. Waterland, R. A. (2006) Assessing the effects of high methionine intake on DNA methylation. J. Nutr., 136, 1706S-1710S.
52. van Engeland, M., Weijenberg, M. P., Roemen, G. M. et al. (2003) Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res., 63, 3133-3137. (Pubitemid 36735864)
53. Vaissiere, T., Hung, R. J., Zaridze, D. et al. (2009) Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res., 69, 243-252.
54. Guz, J., Foksinski, M., Siomek, A., Gackowski, D., Rozalski, R., Dziaman, T., Szpila, A. and Olinski, R. (2008) The relationship between 8-oxo-7,8-dihydro-2′-deoxyguanosine level and extent of cytosine methylation in leukocytes DNA of healthy subjects and in patients with colon adenomas and carcinomas. Mutat. Res., 640, 170-173.
55. Herceg, Z. (2007) Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis, 22, 91-103.
56. Singal, R. and Ginder, G. D. (1999) DNA methylation. Blood, 93, 4059-4070.
57. Laird, P. W. (2003) The power and the promise of DNA methylation markers. Nat. Rev. Cancer, 3, 253-266.
58. Balch, C., Montgomery, J. S., Paik, H.-I., Kim, S., Huang, T. H.-M. and Nephew, K. P. (2005) New anti-cancer strategies: epigenetic therapies and biomarkers. Fron. Biosci., 10, 1887-1931.
59. Zhu, J. and Yao, X. (2009) Use of DNA methylation for cancer detection: promises and challenges. Int. J. Biochem. Cell Biol., 41, 147-154.
60. Greger, V., Passarge, E., Hopping, W., Messmer, E. and Horsthemke, B. (1989) Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum. Gen., 83, 155-158.
61. Jones, A. P. and Baylin, S. B. (2002) The fundamental role of epigenetic events in cancer. Nat. Rev. Genet., 3, 415-428.
62. Baylin, S. B. (2005) DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol., 2, S4-S11.
63. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J. P., Davidson, N. E., Sidransky, D. and Baylin, S. B. (1995) Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55, 4525-4530.
64. Herman, J. G. (1996) Hypermethylation-associated inactivation indicates a tumor suppressor role for p15 (INK4B). Cancer Res., 56, 722-727.
65. Esteller, M., Silva, J. M., Dominguez, G. et al. (2000) Promoter hypermethylation is a cause of BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl Cancer Inst., 92, 564-569. (Pubitemid 30212318)
66. Herman, J. G., Latif, F., Weng, Y. et al. (1994) Silencing of the VHL tumor suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA., 91, 9700-9704.
67. Herman, J. G., Umar, A., Polyak, K. et al. (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl Acad. Sci. USA, 95, 6870-6875.
68. Issa, J. P. (1994) Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat. Genet., 7, 536-540.
69. Hahnel, R., Harvey, J. and Kay, P. (1996) Hypermethylation of the myogenic gene Myf-3 in human breast carcinomas. Anticancer Res., 16, 2111-2115. (Pubitemid 26270734)
70. Yoshiura, K., Kanai, Y., Ochiai, A., Shimoyama, Y., Sugimura, T. and Hirohashi, S. (1995) Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc. Natl Acad. Sci. USA, 92, 7416-7419.
71. Zion, M., Yehuda, D. B., Avraham, A., Cohen, O., Wetzler, M., Melloul, D. and Neriah, Y. B. (1994) Progressive de novo methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc. Natl Acad. Sci. USA., 91, 10722-10726.
72. Dimitrijevic, B. (2005) Cancer epigenome: a review. Arch. Oncol., 13, 108-114.
73. Shah, R., Smith, P., Purdie, C., Quinlan, P., Baker, L., Aman, P., Thompson, A. M. and Crook, T. (2009) The prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer. Br. J. Cancer., 100, 1687-1696.
74. Mayor, R., Casadome, L., Azuara, D., Moreno, V., Clark, S. J., Capella, G. and Peinado, M. A. (2009) Long-range epigenetic silencing at 2q14.2 affects most human colorectal cancers and may have application as a non-invasive biomarker of disease. Br. J. Cancer., 100, 1534-1539.
75. deVos, T., Tetzner, R., Model, F. et al. (2009) Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin. Chem., 55, 1337-1346.
76. Esteller, M. (2003) Relevance of DNA methylation in the management of cancer. Lancet Oncol., 4, 351-358.
77. Lyko, F. and Brown, R. (2005) DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J. Natl Cancer Inst., 97, 1498-1506. (Pubitemid 41631949)
78. Brueckner, B., Kuck, D. and Lyko, F. (2007) DNA methyltransferase inhibitors for cancer therapy. Cancer J., 13, 17-22.
79. Sorm, F., Piskala, A., Cihak, A. and Vesely, J. (1964) 5-Azacytidine, a new, highly effective cancerostatic. Experientia, 20, 202-203.
80. Brueckner, B., Boy, R. G., Siedlecki, P., Musch, T., Kliem, H. C., Zielenkiewicz, P., Suhai, S., Wiessler, M. and Lyko, F. (2005) Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res., 65, 6305-6311. (Pubitemid 40994416)
81. De Abreu, R., Lambooy, L., Stet, E., Vogels-Mentink, T. and van den Heuvel, L. (1995) Thiopurine induced disturbance of DNA methylation in human malignant cells. Advan. Enzyme Regul., 35, 251-263.
82. Gore, S. D., Jones, C. and Kirkpatric, P. (2006) Decitabine. Drug Discov. Today., 5, 891-892.
83. Gopisetty, G., Ramachandran, K. and Singal, R. (2006) DNA methylation and apoptosis. Mol. Immunol., 43, 1729-1740.
84. Steele, N., Finn, P., Brown, R. and Plumb, J. A. (2009) Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br. J. Cancer., 100, 758-763.
85. Yoo, C. B., Cheng, J. C. and Jones, P. A. (2004) Zebularine: a new drug for epigenetic therapy. Biochem. Soc. Trans., 32, 910-912.
86. Rao, S. P., Rechsteiner, M. P., Berger, C., Sigrist, J. A., Nadal, D. and Bernasconi, M. (2007) Zebularine reactivates silenced E-cadherin but unlike 5-Azacytidine does not induce switching from latent to lytic Epstein-Barr virus infection in Burkitt's lymphoma Akata cells. Mol. Cancer., 6, 3-8.
87. Goffin, J. and Eisenhauer, E. (2002) DNA methyltransferase inhibitors: state of the art. Annal. Oncol., 13, 1699-1716.
88. Fang, M. Z., Wang, Y., Ai, N., Hou, Z., Sun, Y., Lu, H., Welsh, W. and Yang, C. S. (2003) Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res., 63, 7563-7570. (Pubitemid 37466673)
89. Fang, M., Chen, D. and Yang, C. S. (2007) Dietary polyphenols may affect DNA methylation. J. Nutr., 137, 223S-228S.
90. Konstantinopoulos, P. A. and Papavassiliou, A. G. (2006) Chromatin-modulating agents as epigenetic anticancer drugs - "the die is cast". Drug Discov. Today, 11, 91-93.
91. Pogribny, I. P. and Beland, F. A. (2009) DNA hypomethylation in the origin and pathogenesis of human diseases. Cell. Mol. Life Sci., 66, 2249-2261.
92. Majumder, P., Pradhan, S. K., Devi, P. K., Pal, S. and Dasgupta, D. (2007) Chromatin as a target for the DNA-binding anticancer drugs. In Kundu, T. K. and Dasgupta, D. (eds.), Chromatin and disease, Springer-Verlag, Berlin, Germany, pp. 145-189.
93. Pearson, H. (2008) Outcry at scale of inheritance project. Nature, 455, 845.
94. Watson, R. E., McKim, J. M., Cockerell, G. L. and Goodman, J. I. (2004) The value of DNA methylation analysis in basic, initial toxicity assessment. Toxicol. Sci., 79, 178-188.
95. Sandhu, J., Kaur, B., Armstrong, C., Talbot, C. J., Steward, W. P., Farmer, P. B. and Singh, R. (2009) Determination of 5-methyl-2′- deoxycitidine in genomic DNA using high performance liquid chromatography- ultraviolet detection. J. Chromatogr. B, 877, 1957-1961.
96. Gu, H., Bock, C., Mikkelsen, T. S., Jäger, N., Smith, Z. D., Tomazou, E., Gnirke, A., Lander, E. S. and Meissner, A. (2010) Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution. Nat. Methods, 7, 133-136.
97. Schones, D. E. and Zhao, K. (2008) Genome-wide approaches to studying chromatin modifications. Natl Rev. Genet., 9, 179-191.
98. Ammerpohl, O., Martín-Subero, J. I., Richter, J., Vater, I. and Siebert, R. (2009) Hunting fir the 5th base: techniques for analyzing DNA methylation. Biochim. Biophys. Acta, 1790, 847-862.
99. Hahn, M. A. and Pfeifer, G. P. (2010) Methods for genome-wide analysis of DNA methylation in intestinal tumors. Mutat. Res., 693, 77-83.
100. Laird, P. W. (2010) Principle and challenges of genome-wide DNA methylation analysis. Nat. Rev. Genet., 11, 191-203.
101. Bock, C., Tomazou, E. M., Brinkman, A. B. et al. (2010) Quantitative comparison of genome-wide DNA methylation mapping technologies. Nat. Biotechnol, 28, 1106-1114.
102. Hayatsu, H. (2008) The bisulfite genomic sequencing used in the analysis of epigenetic states, a technique in the emerging environmental genotoxicology research. Mutat. Res., 659, 77-82.
103. Song, C.-X., Szulwach, K. E., Fu, Y. et al. (2010) Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat. Biotechnol, 29, 68-72.
104. Bartoszek, A., Sielenko, A. and Wesiora, M. (2003) A versatile method employing basic techniques of genetic engineering to study the ability of low molecular weight compounds to bind covalently with DNA in cell-free system. Anal. Biochem., 313, 53-59.
105. Sadikovic, B., Andrews, J. and Rodenhiser, D. I. (2007) DNA methylation analysis using CpG microarrays is impaired in benzopyrene exposed cells. Toxicol. Appl. Pharamacol., 225, 300-309.
106. Okamoto, A. (2009) Chemical approach toward efficient DNA methylation analysis. Org. Biomol. Chem., 7, 21-26.
107. Hodges-Garcia, Y. and Hagerman, P. J. (1992) Cytosine methylation can induce local distortions in the structure of duplex DNA. Biochemistry, 31, 7595-7599.
108. Wang, G., Carbajal, S., Vijg, J., DiGiovanni, J. and Vasquez, K. M. (2008) DNA structure-induced genomic instability in vivo. J. Natl Cancer Inst., 100, 1815-1817.
109. Sen, D. and Crothers, D. M. (1986) Influence of DNA-binding drugs on chromatin condensation. Biochemistry, 25, 1503-1509.
110. Swenberg, J. A., Richardson, F. C., Boucheron, J. A. and Dyroff, M. C. (1985) Relationship between DNA adduct formation and carcinogenesis. Environ. Health Perspect., 62, 17-24.
111. Beland, F.A. and Poireier,M. C. (1994) DNA adducts and their consequences. In Tardiff, R. G., Lohman, P. H. M., Wogan, G. N. (eds.), Methods to assess DNA damage and repair: interspecies comparison. pp. 24-54.
112. Millard, J. T. (1996) DNA modifying agents as a tools for studying chromatin structure. Biochimie, 78, 803-816.
113. Hu, W., Feng, Z. and Tang, M. S. (2003) Preferential carcinogen-DNA adduct formation at codons 12 and 14 in the human K-ras gene and their possible mechanisms. Biochemistry, 42, 10012-10023. (Pubitemid 37012877)
114. Yoon, J.-H., Smith, L. E., Feng, Z., Tang, M. S., Lee, C.-S. and Pfeifer, G. P. (2001) Methylated CpG dinucleotides are the preferential targets for G-to-T transversion mutations induced by benzo[a]pyrene diol epoxide in mammalian cells: similarities with the p53 mutation spectrum in smoking-related lung cancer. Cancer Res., 61, 7110-7117. (Pubitemid 32946502)
115. Pavanello, S., Bollati, V., Pesatori, A. C., Kapka, L., Bolognesi, C., Bertazzi, P. A. and Baccarelli, A. (2009) Global and gene-specific promoter methylation changes are related toanti-B[a]PDE-DNA adduct levels and influence micronuclei levels in polycyclic aromatic hydrocarbon-exposed individuals. Int. J. Cancer., 125, 1692-1697.
116. Bagnyukova, T. V., Tryndyak, V. P., Montgomery, B., Churchwell, M. I., Karpf, A. R., James, A. R., Muskhelishvili, L., Beland, F. A. and Pogribny, I. P. (2008) Genetic and epigenetic changes in rat preneoplastic liver tissue induced by 2-acetylaminofluorene. Carcinogenesis, 29, 638-646. (Pubitemid 351404882)
117. Liu, W.-b., Liu, J.-y., Ao, L., Zhou, Z.-y., Zhou, Z.-h., Cui, Z.-h., Yang, H. and Cao, J. (2009) Dynamic changes in DNA methylation during multistep rat lung carcinogenesis induced by 3-methylchloranthrene and diethylnitrosamine. Toxicol. Lett., 189, 5-13.
118. Sadikovic, B. and Rodenhiser, D. (2006) Benzo[a]pyren exposure disrupts DNA methylation and growth dynamics in breast cancer. Toxicol. Appl. Pharamacol., 216, 456-468.
119. Zou, Y., Shell, S. M., Utzat, D. C., Luo, C., Yang, Z., Geacintov, N. E. and Basu, A. K. (2003) Effects of DNA adduct structure and sequence context on strand opening of repair intermediates and incision by UvrABC nuclease. Biochemistry, 42, 12654-12661.
120. Jiricny, J. (2002) DNA repair: bioinformatics helps reverse methylation damage. Current Biol., 12, R846-R848.
121. Pfohl-Leszkowicz, A., Grosse, Y., Carriere, V., Cugnenc, P.-H., Berger, A., Carnot, F., Huc, A., Beaune, P. and de Waziers, I. (1995) Impaired DNA methylation and DNA adduct concentrations in human peritumoral and tumoral colorectal samples and normal colon. Clin. Chem., 41, 1924-1926.
122. Johnson, W. S., He, Q.-Y. and Tomasz, M. (1995) Selective recognition of the m5CpG dinucleotide sequence in DNA by mitomycin C for alkylation and cross-linking. Bioorg. Med. Chem., 3, 851-860.
123. Cutts, S. M., Swift, L. P., Raphaeli, A., Nudelman, A. and Phillips, D. R. (2003) Sequence specifity of adriamycin-DNA adducts in human tumor cells. Mol. Cancer Ther., 2, 661-670.
124. Parker, B. S., Cutts, S. M. and Phillips, D. R. (2001) Cytosine methylation enhances mitoxantrone-DNA adduct formation at CpG nucleotides. J. Biol. Chem., 276, 15953-15960.
125. Parker, B. S., Buley, T., Evison, B. J., Cutts, S. M., Neumann, G. M., Iskander, M. N. and Phillips, D. R. (2004) A molecular understanding of mitoxantrone-DNA adduct formation. J. Biol. Chem, 279, 18814-18823.
126. Galea, A. M. and Murray, V. (2002) The interaction of cisplatin and analogues with DNA in reconstituted chromatin. Biochim. Biophys. Acta, 1579, 142-152.
127. Fichtinger-Schepman, A. M., van der Veer, J. L., den Hartog, J. H., Lohman, P. H. and Reedijk, J. (1985) Adducts of the antitumor drug cis-diamminedichloroplatinum( II) with DNA: formation, identification, and quantitation. Biochemistry, 29, 707-713.
128. Davies, N. P., Hardman, L. C. and Murray, V. (2000) The effect of chromatin structure on cisplatin damage in intact human cells. Nucleic Acids Res., 28, 2954-2958. (Pubitemid 30599271)
129. 32P- postlabelling analysis of nucleobases involved in the formation DNA adducts by antitumor 1-nitroacridines. Chem. Biol. Interact., 103, 131-139.
130. Woynarowski, J. M., McNamee, H., Szmigiero, L., Beerman, T. A. and Konopa, J. (1989) Induction of DNA-protein crosslinks by antitumor 1-nitro-9-aminoacridines in L1210 leukemia cells. Biochem. Pharmacol, 38, 4095-4101.
131. Gniazdowski, M., Ciesielska, E. and Szmigiero, L. (1981) Some properties of the irreversible complexes of nitracrine (Ledakrin, C-283) with polynucleotides. Chem. Biol. Interact, 355, 355-366.
132. Barton, T. S., Robaire, B. and Hales, F. H. (2005) Epigenetic programming in the preimplantation rat embryo is disrupted by chronic parental cyclophosphamide exposure. Proc. Natl Acad. Sci. USA, 102, 7865-7870.
133. Phillips, D. H. (2001) Understanding the genotoxicity of tamoxifen? Carcinogenesis, 22, 839-849.
134. Tryndyak, V. P., Muskhelishvili, L., Kovalchuk, O., Rodriguez-Juarez, R., Montgomery, B., Churchwell, M. I., Ross, S. A., Beland, F. A. and Pogribny, I. P. (2006) Effect of long-term tamoxifen exposure on genotoxic and epigenetic changes in rat liver: implications for tamoxifen-induced hepatocarcinogenesis. Carcinogenesis, 27, 1713-1720. (Pubitemid 44288061)
135. Tryndyak, V. P., Kovalchuk, O., Muskhelishvili, L., Montgomery, B., Rodriguez-Juarez, R., Melnyk, S., Ross, S. A., Beland, F. A. and Pogribny, I. P. (2007) Epigenetic reprogramming of liver cells in tamoxifen-induced rat hepatocarcinogenesis. Mol. Carcinogenesis, 46, 187-197.
136. Yauk, C., Polyzos, A., Rowan-Caroll, A. et al. (2008) Germ-line mutations, DNA damage, and global hypermethylation in mice exposed to particulate air pollution in an urban/industrial location. Proc. Natl Acad. Sci. USA, 105, 605-610.
137. Jaffe, L. A. (2003) Epigenetic theories of cancer initiation. Adv. Cancer Res., 30, 209-230.